Among these strategies, glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose cotransporter-2 (SGLT2) inhibitors have recently shown some benefit as adjuvant therapy with insulin in the treatment of patients with T1DM (6). This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.